Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
213
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
A look into newly listed Glencore’s valuation
A new ASX heavyweight with coal, copper and trading exposure.
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
We’ll be watching Muse agent adoption, revenue growth, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,882.21 | 43.72 | 0.56% |
| DAX 40 | 25,441.31 | 136.89 | 0.54% |
| Dow JONES (US) | 52,495.88 | 529.85 | 1.02% |
| FTSE 100 | 10,742.33 | 9.33 | 0.09% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,424.82 | 6.07 | -0.02% |
| Nikkei 225 | 64,621.24 | 545.82 | 0.85% |
| NZX 50 Index | 13,761.29 | 129.60 | 0.95% |
| S&P 500 | 7,712.57 | 21.84 | 0.28% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,713.03 | 22.34 | -0.60% |